Pular para o conteúdo principal
Ranking Invest

ALIM - Alimera Sciences, Inc.

Segmento: HealthcareAlimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Análise Ranking Invest

Valuation estimado
-$ 17.70 Mi
Último Balanço Atualizado: 2T2024

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 38.79 Mi

Dívida Líquida

$ 61.30 Mi

L4T

-$ 14.70 Mi

MM4T

-14.90%

Indicadores Básicos

ROE

-37.89%

Índices de Previsibilidade

Receita Líquida

E0.19

Lucro

C0.41

Margem

D0.75

Índices de Tendência

Receita Líquida

B8.58

Lucro

F-4.91

Margem

E-2.64

Índices de Endividamento

DIV/PAT

1.58

DIV/L4T

-4.17

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.